Meeting Registration 

Live Welcome & Introductions
Ola Landgren, University of Miami 

Session I: MRD testing in smoldering myeloma: new horizons!
Chair: Benjamin Diamond, University of Miami

• From CENTAURUS to AQUILA trials: Meletios Dimopoulos, University of Athens School of Medicine
• NCI KRd-R trial long-term follow up: Elizabeth Hill, National Cancer Institute
• ASCENT trial: Shaji Kumar, Mayo Clinic
• Immuno-PRISM and CAR-PRISM trials: Omar Nadeem, Dana-Farber Cancer Institute
• REVIVE trial: Ola Landgren, University of Miami 

Panel discussion (10 minutes): Benjamin Diamond, Meletios Dimopoulos, Elizabeth Hill, Omar Nadeem, Ola Landgren, Malin Hultcrantz (Memorial Sloan Kettering Cancer Center), Hans Lee (Sarah Cannon Research Institute), Paola Neri (University of Calgary), Adam Cohen (University of Pennsylvania)

Session II: Panel discussion – Is high-risk SMM the new treatment indication for all patients? Role of depth of response?
Panel chair: Ola Landgren, University of Miami (chair will ask questions and lead discussion on “today and the future”)

Discussants: Nicole Gormley, (FDA), Hearn Jay Cho (MMRF), Malin Hultcrantz (Memorial Sloan Kettering Cancer Center), Salomon Manier (Lille University Hospital), Adam Cohen (University of Pennsylvania)

Coffee Break & Exhibition

Session III: New insights on MRD negativity in newly diagnosed myeloma                                                              
Chair: Gil Hevroni, University of Miami

• MANHATTAN trial, long-term update: Nehar Korde, Memorial Sloan Kettering Cancer Center
• MagnetisMM-6 trial, part 2: Hang Quach, University of Melbourne
• IFM2021-01 TecLille trial: Salomon Manier, Lille University Hospital
• MajesTEC-5 trial: Marc Raab, University of Heidelberg
• ADVANCE 2.0 trial: Kellye Koubek, University of Miami 

Panel discussion (10 minutes): Gil Hevroni, Neha Korde, Salomon Manier, Marc Raab, Kellye Koubek, Lawrence Boise (Emory University)

SESSION IV: Panel discussion – Newly diagnosed multiple myeloma and MRD: What are the trends?
Panel chair: Ola Landgren, University of Miami (chair will ask questions and lead discussion on “today and the future”)

Discussants: Jenny Ahlstrom (HealthTree), Heather Cooper Ortner (IMF), Hearn Jay Cho (MMRF), Nicole Gormley (FDA), Robert Orlowski (MD Anderson Cancer Center), Gareth Morgan (NYU Langone Health), Charlotte Pawlyn (The Institute of Cancer Research)

Session V: MRD driven treatment trials
Chair: Rafat Abonour, University of Miami

Panel discussion (10 minutes): Rafat Abonour, Benjamin Derman, Brian Walker, Adam Cohen, Dickran Kazandijian, Robert Orlowski, Malin Hultcrantz (Memorial Sloan Kettering Cancer Center), Benjamin Diamond (University of Miami)

Lunch & Fireside Chat
Nicole Gormley, FDA & Ola Landgren, University of Miami

Session VI: Panel discussion – MRD and treatment decisions: Are we there yet?
Panel chair: Rafat Abonour, University of Miami

Discussants: Jenny Ahlstrom (HealthTree), Heather Cooper Ortner (IMF), Hearn Jay Cho (MMRF)

Session VII: MRD in relapsed/refractory myeloma
Chair: Diko Kazandjian, University of Miami

• DREAMM-7 trial: Vania Hungria, Clínica São Germano
• ARLOCEL trial with MEZI: Susan Bal, University of Alabama
• FAST CAR-T trial: Juan Du, Shanghai Changzheng Hospital
• Redirectt-1 trial: Maria-Victoria Mateos, University of Salamanca
• iMMagine-1 trial: TBC
  
• REKINDLE trial: Benjamin Diamond, University of Miami
• LINKER-MM4 trial: Robert Orlowski, MD Anderson Cancer Center

Panel discussion (10 minutes):Diko Kazandjian, Juan Du, María-Victoria Mateos, Benjamin Diamond, Robert Orlowski, Sikander Ailawadi (Mayo Clinic), Adam Cohen (University of Pennsylvania), Malin Hultcrantz (Memorial Sloan Kettering Cancer Center)

Coffee Break & Exhibition

Session VIII: Emerging MRD technologies
Chair: David Coffey, University of Miami 

• Update on ClonoSEQ MRD data: Malin Hultcrantz, Memorial Sloan Kettering Cancer Center
• Cell free DNA tracking: Benjamin Diamond, University of Miami
• Update on MALDI TOF MS and clonotypic peptides: Katie Thoren, University of Miami
• Update on FLC tracking: Kazunori Murata, University of Miami
• CD38 targeted immunoPET: Gary Ulaner, University of Southern California

Panel discussion (10 minutes):Malin Hultcrantz, Benjamin Diamond, Katie Thoren, Kazunori Murata, Robert Orlowski (MD Anderson Cancer Center), Gareth Morgan (NYU Langone Health), Lawrence Boise (Emory University)

Session IX: “Emerging MRD technologies: What are the clinical and scientific needs?”
Panel chair: Ola Landgren, University of Miami

Discussants: Jenny Ahlstrom (HealthTree), Heather Cooper Ortner (IMF), and George Mulligan (MMRF)

Wrap Up and Adjourn
Jenny Ahlstrom (HealthTree), Heather Cooper Ortner (IMF), George Mulligan (MMRF), and Ola Landgren (University of Miami)

Exhibition, Reception & Refreshments